STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1914 by analyst upside · 2026-06-27
ERAS
Erasca, Inc.
Healthcare · Market Cap $5B · P/E 0x
ANALYST PRICE TARGET
+31.2%
implied upside to consensus target
Current Price $16.01
Consensus Target $21.0
Bull Target $30.0
Bear Target $12.0
Analysts Covering 10
ANALYST CONSENSUS — BUY
Strong Buy
2
Buy
6
Hold
1
Sell
1
52-Week Low $1.21
52-Week High $24.28
YTD Return +346.0%
FUNDAMENTALS
Market Cap $5B
P/E Ratio (TTM) N/A
Forward P/E -27.9x
EPS (TTM) $-0.93
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.21
52-Week High $24.28
Current Price $16.01
Bear Target $12.0
Bull Target $30.0
● Now $16.01 ● Target $21.0
TRADING DATA
Avg Volume 6.7M
YTD Return +346.0%
Analyst Count 10
Consensus Buy
Upside to Target +31.2%
Last Updated 2026-06-27

ANALYST SUMMARY

Erasca, Inc. (ERAS) is currently trading at $16.01 with a Wall Street consensus price target of $21.0, implying potential upside of 31.2% over the next 12 months. 10 analysts currently cover ERAS, with a consensus rating of Buy — 80% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $30.0, while the most cautious has a target of $12.0.

ERAS operates in the Healthcare sector with a market capitalisation of $5B. The stock is up 346.0% year-to-date and is currently trading near the upper end of its 52-week range of $1.21 – $24.28.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ERAS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

B of A Securities ↑ Upgrade
Underperform → Neutral 2026-06-04 Building track record
Mizuho — Reiterated
Outperform → Outperform 2026-05-12 Building track record
Stifel — Reiterated
Buy → Buy 2026-04-27 Building track record
JP Morgan — Reiterated
Overweight → Overweight 2026-03-18 43% win rate (7 calls)
Guggenheim — Reiterated
Buy → Buy 2026-03-16 62% win rate (8 calls)
Piper Sandler — Reiterated
Overweight → Overweight 2026-03-13 14% win rate (7 calls)
Mizuho — Reiterated
Outperform → Outperform 2026-03-13 Building track record
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-03-13 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →